DAMORA THERAPEUTICS INC (DMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$30.00+0.67%
Close 2026-07-07 · 1-day change
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading DMRA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DMRA free→Damora is stabilizing leadership with a new CEO and CFO successor. The company has $535 million in cash as of early 2026, supporting its operations. Operating losses are managed around $30 million per quarter while advancing drug development. Inclusion in Russell 2000 Growth and positive analyst views may improve visibility.
Damora remains loss-making with negative EPS expected through 2027. Leadership changes have been volatile, including CFO departure and accounting firm dismissal. Operating losses and cash burn continue, risking liquidity. The biotech pipeline faces typical clinical and regulatory risks.
The stock trades about 25% below our fair value near $40, reflecting cautious market views. The market expects continued losses and uncertain growth, while our view sees potential if leadership and cash management stabilize.
Breaks if: cash and equivalents fall below $500 million by 2026-Q4
Ensure sufficient cash and capital through equity offerings and cash management to support operations and development.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. The company raised capital via a public offering of 14.5 million shares at $19.00 each and reported $535 million cash and equivalents as of 2026-Q1. This supports liquidity needs amid ongoing operating losses, indicating active capital resource management.
“Company had cash and cash equivalents of approximately $535 million as of February 28, 2026.”
“Entered underwriting agreement for public offering of 14,473,685 shares at $19.00 per share.”
Breaks if: CEO or CFO roles become vacant or unstable again within next 4 quarters
Manage CEO and CFO transitions to stabilize leadership and support company strategy execution.
Stated as a priority in 3 of last 3 quarters. The company experienced CEO and CFO transitions in 2026-Q1 and 2026-Q2, with a new CEO appointed and CFO departure announced with successor named. Management is actively managing leadership changes to stabilize the company.
“Jennifer Jarrett was appointed as President and Chief Executive Officer.”
“Lori Firmani is departing as Chief Financial Officer with a successor appointed.”
“Dr. Schambye resigned from his roles as CEO and President.”
Breaks if: operating loss worsens beyond -$30 million per quarter over next 4 quarters
Control operating expenses and cash burn to extend runway while advancing development programs.
Stated as a priority in 6 of last 6 quarters. Operating losses ranged from negative $2.6 million in 2025-Q1 to negative $30.8 million in 2026-Q1, with net losses similarly negative and cash from operations negative $20.6 million in 2026-Q1. The trajectory shows persistent operating losses and cash burn, indicating ongoing cost management challenges.
“Operating income was negative $30.8 million and net income negative $27.8 million.”
“Operating income was negative $201.7 million and net income negative $200.7 million.”
“Operating income was negative $3.2 million and net income negative $3.1 million.”
“Operating income was negative $3.4 million and net income negative $3.4 million.”
“Operating income was negative $2.6 million and net income negative $2.5 million.”
“Operating income was negative $7.1 million and net income negative $6.7 million.”